[{"id":"db35acfe-81ce-4688-a732-b422e893e950","acronym":"STIMVAX","url":"https://clinicaltrials.gov/study/NCT04444622","created_at":"2021-01-18T21:23:09.853Z","updated_at":"2024-07-02T16:35:16.269Z","phase":"Phase 2","brief_title":"Immunotherapy for Third Line Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04444622 - STIMVAX","lead_sponsor":"Immunovative Therapies, Ltd.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AlloStim (bioengineered allogeneic immune cells)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 07/12/2021","start_date":" 07/12/2021","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-03-06"},{"id":"2bfc97c6-0dcd-438e-822b-92be5bb4f42d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02018419","created_at":"2021-01-18T09:14:12.022Z","updated_at":"2024-07-02T16:36:51.040Z","phase":"Phase 1/2","brief_title":"Increased Frequency of AlloStim(TM) Dosing in Combination With Cryoablation in Metastatic Breast Cancer Patients","source_id_and_acronym":"NCT02018419","lead_sponsor":"Immunovative Therapies, Ltd.","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • AlloStim (bioengineered allogeneic immune cells)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/01/2014","start_date":" 03/01/2014","primary_txt":" Primary completion: 03/01/2014","primary_completion_date":" 03/01/2014","study_txt":" Completion: 03/01/2014","study_completion_date":" 03/01/2014","last_update_posted":"2020-01-22"},{"id":"3b0bb42f-cc9f-44f9-a84c-b0cb0f672ccd","acronym":"","url":"https://clinicaltrials.gov/study/NCT02380443","created_at":"2021-01-18T11:20:33.151Z","updated_at":"2024-07-02T16:36:51.079Z","phase":"Phase 2a","brief_title":"AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer","source_id_and_acronym":"NCT02380443","lead_sponsor":"Immunovative Therapies, Ltd.","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AlloStim (bioengineered allogeneic immune cells)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 09/01/2016","start_date":" 09/01/2016","primary_txt":" Primary completion: 03/01/2018","primary_completion_date":" 03/01/2018","study_txt":" Completion: 09/01/2018","study_completion_date":" 09/01/2018","last_update_posted":"2020-01-22"},{"id":"580ba128-2752-4bcb-b5b4-8e70468f9817","acronym":"","url":"https://clinicaltrials.gov/study/NCT01741038","created_at":"2021-01-18T07:37:17.218Z","updated_at":"2024-07-02T16:36:51.075Z","phase":"Phase 2/3","brief_title":"AlloStim® In-Situ Vaccine in Pre-Treated Metastatic Colorectal Cancer","source_id_and_acronym":"NCT01741038","lead_sponsor":"Immunovative Therapies, Ltd.","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • KRAS wild-type • RAS wild-type","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • AlloStim (bioengineered allogeneic immune cells)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2017","start_date":" 12/01/2017","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 10/01/2020","study_completion_date":" 10/01/2020","last_update_posted":"2020-01-22"}]